Weight Loss Injection May Significantly Reduce Cancer Risk
Recent research indicates that a weight loss injection could nearly cut the risk of obesity-related cancers by half. This discovery has drawn attention from cancer specialists, who describe the findings as “transformative,” suggesting it might usher in a new era for preventive cancer care.
Obesity is linked to 13 different cancers, and while losing weight can lower that risk, researchers believe that weight loss injections could offer a stronger protective effect.
In a study involving 6,000 adults without a cancer history, researchers looked at those who either had undergone bariatric surgery or were using glucagon-like peptide-1 receptor agonists (GLP-1RAS) such as liraglutide (Saxenda), exenatide (Vinetta), or duraglutide (Trulicity). These drugs mimic the body’s hormonal signals, helping to lower blood sugar levels and increase feelings of fullness.
The findings revealed that individuals who had bariatric surgery lost roughly double the weight compared to those on medication, with both methods showing similar cancer risk reductions, as stated in a study presented at the European Conference on Obesity in Malaga, Spain.
According to the research, bariatric surgery reduces cancer risk by 30-42%. Given the effectiveness of surgery, researchers concluded that weight loss medications might be superior in preventing cancers associated with obesity.
Professor Dror Dicker from Hasharon Hospital noted that the protective effects of GLP-1RAS could stem from several mechanisms, including a decrease in inflammation. He speculated that upcoming drugs could further enhance these benefits, though future studies are necessary to ensure they don’t elevate the risk of other cancers.
Another study presented at the same conference compared two weight loss injections: Mounjaro and Wegovy. Results showed that patients using Mounjaro lost about 50% more weight than those on Wegovy, shedding an average of 20.2% versus 13.7% over the study period.
Reacting to these revelations, Professor Mark Lawler from Queen’s University Belfast emphasized that while these are observational results needing careful interpretation, they are certainly exciting. He pointed out that while bariatric surgery already reduces cancer risk by a third, this new data hints that GLP-1 treatments could lower that risk by nearly half.
He further explained that since GLP-1 affects inflammation, which is closely linked to cancer, the implications are significant. Additional research is needed to understand its full potential, but there’s an intriguing possibility that GLP-1 injections could help prevent various cancers, including breast and colorectal cancers, which are notoriously hard to treat.
Professor Jason Halford from the University of Leeds advocated for testing the drug in newly diagnosed cancer patients to see if it might improve survival rates. He remarked on the potential of this approach, highlighting the growing connection between obesity and cancer.
A coalition of 54 global experts gathered at the conference also called for prioritizing the use of weight loss medications as a preventive measure against cancer. Meanwhile, British scientists from the University of Manchester, supported by Cancer Research UK, are gearing up for a large clinical trial expected to encompass tens of thousands of patients within the next few years.
Dr. Matthew Harris from the Manchester Cancer Research Centre emphasized the great weight loss potential of the injection and its implications for broader public health intervention.
